Waldenström macroglobulinaemia (WM) is a distinct B-cell lymphoproliferative disorder characterised by an immunoglobulin IgM monoclonal gammopathy and bone marrow infiltration by lymphoplasmacytic lymphoma (LPL).1, 2 Clinical features may be related to overall disease burden, such as anaemia, constitutional symptoms, or may be directly attributable to the IgM paraprotein. The term IgM-related disorders denotes the presence of clinical features attributable to the IgM paraprotein in the absence of bone marrow lymphoplasmacytic infiltration.1
Declaration of Interests
The BSH paid the expenses incurred during the writing of this guidance. None of the authors had conflicts of interest to declare. All authors have made a declaration of interests to the BSH and Task Force Chairs which may be viewed on request.